Saliva, as a biofluid, is inexpensive and non-invasive to obtain, and provides a vital tool to 32 investigate oral health and its interaction with systemic health conditions. There is growing 33 interest in salivary biomarkers for systemic diseases, notably cardiovascular disease. Whereas 34 hundreds of genetic loci have been shown to be involved in the regulation of blood metabolites 35 leading to unprecedented insights into the pathogenesis of complex human diseases, little is 36 known about the impact of host genetics on salivary metabolites. Here we report the first 37 genome-wide association study exploring 476 salivary metabolites in 1,419 subjects of European 38 ancestry from the TwinsUK cohort (discovery phase). A total of 14 salivary metabolites were 39 significantly associated (p<10 -10 ) with genetic variants that mapped to 11 distinct loci, most of 40 which replicated in the Study of Health in Pomerania (SHIP-2) cohort. Interestingly, while only a 41 limited number of the loci that are known to regulate blood metabolites were also associated with 42 salivary metabolites in our study, we identified several novel saliva-specific locus-metabolite 43 associations, including associations for the AGMAT (with the metabolites 4-guanidinobutanoate 44 and beta-guanidinopropanoate), ATP13A5 (with the metabolite creatinine) and DPYS (with the 45 metabolites 3-ureidopropionate and 3-ureidoisobutyrate) loci. Our study suggests that there are 46 biological pathways which are specific to the regulation of the salivary metabolome. In addition, 47 some of our findings may have clinical relevance, such as the utility of the pyrimidine (uracil) 48 degradation metabolites in predicting 5-fluorouracil toxicity and the role of the agmatine 49 pathway metabolites as biomarkers of oral health. 50
Introduction 51
Metabolic reactions pervade every aspect of human physiology, abnormalities in which underlie 52 a plethora of human diseases 1 . Investigating the genetic underpinnings of population-wide 53 variation of metabolites can offer novel insights into human metabolism and diseases, in addition 54 to providing potential therapeutic targets to modulate metabolite levels. Large-scale genetic 55 association studies have so far identified hundreds of loci that regulate the levels of metabolites 56 in blood 2-6 , and to a lesser extent in other biospecimens as well [7] [8] [9] . Previous studies have shown 57 that genetic variants on average explain a greater proportion of trait variance for metabolites 58 compared to what is generally observed for complex traits 3,4 , highlighting the utility of 59 metabolites as intermediate traits for dissecting the genetics of complex diseases. 60
Saliva is an abundantly produced biofluid, and it can be obtained in an inexpensive and non-61 invasive manner, without the need for healthcare professionals. It is mainly composed of water 62 (>99%) and several other minor constituents such as mucous, digestive enzymes, cytokines, 63 immunoglobulins, antibacterial peptides and low molecular weight metabolites 10 . 64 among others [15] [16] [17] [18] [19] . Therefore, investigation of salivary metabolites could not only provide novel 74 biomarkers but also further our understanding of biological pathways underlying oral as well as 75 general health conditions. 76
Here we report a genome-wide association analysis (based on 1000 Genomes imputed data) for 77 476 salivary metabolites in the population-based TwinsUK study, followed by replication in the with LD (r 2 ) > 0.2, and checked for additional metabolite associations at a significance threshold 149 of p<10 -6 (corresponding to p=0.05, corrected for 476 metabolites and a prior assumption of 150 about 100 associated loci). 151 152 (iii) Testing the significantly associated loci using metabolite data from other 153 biospecimens 154 For each locus-metabolite association, we further assessed the most significant variant-155 metabolite pair by using measurements for the respective metabolite in serum 4 and faecal 156 samples 7 of the TwinsUK subjects (provided the metabolite was measured in that biospecimen). 157
We tested only those serum and faecal samples that overlapped with the ones in saliva and were 158 collected within 5 years of the saliva samples (in order to ensure that, for a given individual, 159 samples from the different biospecimens being tested were obtained within a certain period of 160 one another). Association testing for serum and faecal metabolites was done using an identical 161 model to that described for the analysis of salivary metabolites. 162 163 (iv) Conditional analysis for the significantly associated loci 164 165 We used approximate conditional analysis, as implemented on GCTA 24 , to test whether any of 166 the associated loci had multiple distinct i.e. secondary association signals, at a "locus-wide" 167 significance threshold of p<10 -5 . For each associated locus, all variants that surpassed the study-168 wide significance threshold (p<10 -10 ) were conditioned on the most significantly associated 169 variant at that locus (using the association summary statistics). For the conditional analysis, we used genotype data from the complete TwinsUK dataset (N=5,654) to model LD patterns 171 between variants. 172
(a) Detection of secondary association signals

(b) Adjustment for periodontal disease status 173
Since salivary metabolites are known to be associated with periodontal disease (PD) 11 , for each 174 locus-metabolite association, we additionally adjusted the most significant variant-metabolite 175 pair for PD status. Self-reported gingival bleeding, and a history of gum disease or tooth mobility 176 were used as indicators of PD in TwinsUK 25 (270 PD cases; 1,083 controls). 177 178 Expression quantitative trait locus (eQTL) analysis 179 We used the version 7 data release of the Genotype-Tissue Expression (GTEx) project (accessed 180 15 April 2019), which was based on RNA-Seq data obtained from 48 non-diseased tissue sites 181 across ~1,000 individuals, to test whether the most significant variant at each associated locus 182 had an eQTL effect on transcripts located within a 1 Mb window of the variant. 183 184 Annotation of associations using reference databases 185 We searched the NHGRI GWAS catalogue (accessed 15 April 2019) for previous disease 186 associations for the significantly associated loci that were identified in our study. We also 187 searched the OMIM database (accessed 15 April 2019) to check the candidate genes at the 188 associated loci for a causal link with inborn errors of metabolism. Moreover, we also queried the 189 HMDB 12 and KEGG 22 databases to identify biochemical pathways and known disease 190 associations for the associated metabolites. for SHIP-2 saliva samples (N=1,000) was performed using an identical process to that described 198 for TwinsUK. 199
Since the method of saliva sample collection in SHIP-2 (chewing on a piece of cotton) meant 200 that the sample thus obtained represented stimulated saliva, normalisation of the metabolite 201 measurements for sample osmolality was not considered necessary. The fact that the salivary 202 osmolality values in SHIP-2 had a much narrower distribution compared to that in TwinsUK 203 verified our rationale ( Figure S1) . 204
For each locus-metabolite association that was identified in the discovery phase, we tested the 205 most significantly associated variant using a linear regression model was fitted on R (version 206 3.5.2). Covariates used in the association model were similar to those used for the discovery 207 phase. 208 209 (III) Testing the significantly associated salivary metabolites with phenotypes 210 of interest 211 We wanted to test how salivary metabolites that were regulated by genetic loci related to relevant 212 phenotypes. For that, we selected the metabolites that were uniquely associated in saliva i.e. the 213 ones for which a genetic association had not been previously reported in blood, and tested them 214 with phenotypes (diseases / traits / adverse drug effects) relating to the metabolite or its associated biochemical pathway. We obtained the relevant phenotype information from the 216 TwinsUK database, selecting one twin per pair (N=1,426). The phenotype association analysis 217 was performed on R (version 3.5.2) by fitting a linear regression model to test the association 218 between the salivary metabolite and the disease / trait / adverse drug effect (adjusted for age and 219 sex). 220
Results
222
Identification of novel genetic loci regulating salivary metabolite levels 223
Primary genome-wide discovery analysis in TwinsUK identified 13 metabolites that were 224 significantly associated with genetic loci after correcting for multiple testing (p<10 -10 ). 225
Furthermore, when we narrowed our analysis to just the loci that were identified in the primary 226 stage, one additional metabolite was found associated (p<10 -6 ). Consequently, a total of 14 227 distinct locus-metabolite associations (hereafter, referred to as 'mQTLs') were identified in the 228 discovery phase of our study. The set of significantly associated variants mapped to 11 distinct 229 genetic loci, which have been referred to by the name(s) of the overlapping or the nearest gene(s) 230 (Figure 1) . Three of those loci (AGMAT, SLC2A9 and DPYS) were associated with two 231 metabolites each ( Table 1 ). In all three instances, the two metabolites regulated by the same 232 locus were correlated (Pearson's r 2 for the metabolite pairs ranged between 0.42 -0.84) ( Figure  233 S2). On the other hand, none of the 14 metabolites that was associated in our study had more 234 than one significant locus. Quantile-quantile (QQ) plots for the significantly associated 235 metabolites are provided in Figure S3 . 236
Of the 11 genetic loci that were identified in the discovery phase, four of them (SLC2A9, 237 DMGDH, FADS2 and ACADS) have previously been reported in association with blood 238 metabolites 2,4,5 ; the remaining seven loci were novel i.e. there were no previously known 239 associations for them with metabolites in blood or any other biospecimens. 240
The AGMAT locus, one of the novel loci identified, was associated with the metabolites 4-241 guanidinobutanoate and beta-guanidinopropanoate. These metabolites are generated as 242 intermediate products in the polyamine synthesis pathway, the main site of action for the enzyme agmatinase (encoded by the AGMAT gene) 26 . The most significantly associated variants for the 244 two metabolites i.e. rs10927806 and rs6690813, respectively, are in high LD with one another 245 (r 2 =0.99), suggesting a shared underlying genetic regulation for the two metabolites by the 246 AGMAT locus. Likewise, the association between the ATP13A5 locus and creatinine (a widely 247 used measure of renal function), observed in our study, has also not been reported previously. 248
Another interesting novel association that we identified pertained to the metabolism of the 249 pyrimidine uracil -the DPYS locus (encodes for the enzyme dihydropyrimidinase, involved in 250 uracil degradation) was associated with the metabolites 3-ureidopropionate and 3-251 ureidoisobutyrate (breakdown products of uracil metabolism). The novel association for the 252 TYMS/ENOSF1 locus with ribonate is also intriguing, since it has previously been shown that 253 ribonate is one of the substrates for the catalytic activity of reverse thymidylate synthase (rTS), 254 the protein product of ENOSF1 27 . Therefore, it appears that ENOSF1, which is the source of anti-255 sense RNA of TYMS, is probably the functional gene mediating the observed association of the 256 TYMS/ENOSF1 locus with salivary ribonate. The associations of the SLC2A9 locus with 257 allantoin, the ABO locus with N-acetylglucosamine/N-acetylgalactosamine, the UGCG locus 258 with glycosyl-N-stearoyl-sphinganine, and the MGP locus with gamma-carboxyglutamate were 259 the remaining mQTLs observed in our study that have not been reported previously. 260
Of the 14 distinct mQTLs that were identified in our study, it was possible to test the most 261 significant variant-metabolite pair for nine mQTLs in both serum and faecal metabolite data in 262
TwinsUK (metabolites corresponding to the remaining five mQTLs were not present in the 263 serum and faecal metabolite datasets). Of them, the associations for the ATP13A5 and DPYS loci 264 did not replicate in serum (p>0.05); while, none of the associations, barring the one for the 265 three biospecimens (for the significantly associated salivary metabolites which were also 267 measured in serum and faecal samples in TwinsUK) demonstrates that the effects of the 268 ATP13A5 and DPYS loci were specific to saliva ( Figure S4) . 269
For none of the mQTLs that was identified, did we find any additional independent association 270 signals after conditioning for the most significant variant at the locus (conditional p>10 -5 for all 271 variants tested at each locus), a finding which was verified by the regional association plots 272 ( Figure S5) . The observation that a single genetic association signal underlies each of the 273 significantly associated metabolites might partly be due to our lack of power to detect secondary 274 signals at these loci. 275
Moreover, the strength of association for the most significant variant-metabolite pair did not 276 change much on adjusting for PD status, for any of the mQTLs (Table S2 ). Hence, it does not 277 appear that the presence of underlying PD has a significant effect on the associations observed in 278 our study. 279
For 8 of the 11 associated loci, it was observed that the most significant variant demonstrated an 280 eQTL effect on at least one transcript in one of the tissues in the GTEx database (no significant 281 eQTL effects were observed for the ATP13A5, SLCA2A9 and ABO loci) ( Table S3 ). In case of 7 282 of those 8 loci (except DPYS), the significant eQTL effect was observed for the overlapping or 283 the nearest gene transcript; and for 5 of those 7 loci (AGMAT, FADS2, DMGDH, TYMS/ENOSF1 284 and UGCG), the eQTL effect was observed in one of the gut-related tissues. While eQTL data 285 for transcripts assayed in the minor salivary glands was available for a small number of donors 286 (N=97) in the GTEx database, none of the significant eQTL effects that we observed was in the 287 salivary tissue. 288
Replication of the discovery phase findings 290
In SHIP-2, we could attempt replication for 9 of the 14 mQTLs that were identified in the 291 discovery phase (metabolites corresponding to the remaining five mQTLs were not measured in 292 SHIP-2). In the initial replication analysis, which was performed using salivary metabolite data 293 that was not normalised for sample osmolality, 8 of the 9 discovery phase associations were 294 replicated (p<0.05), with the direction of effect consistent with that observed in TwinsUK ( Table  295 2). The association between the ABO locus and N-acetylglucosamine/N-acetylgalactosamine was 296 the only finding from the discovery phase that did not replicate in SHIP-2. When we repeated the 297 replication analysis in SHIP-2 with metabolite data that was normalised for the sample 298 osmolality, the strength of all the associations was comparatively reduced (Table S4) . 299 300 Phenotypic associations for salivary metabolites 301 Majority of the loci that were associated in our study have been reported in relation with GWAS 302 traits, inborn errors of metabolism and / or clinically relevant biochemical pathways ( Table 3) . 303
We further tested the salivary metabolites associated with the DPYS, AGMAT and ATP13A5 loci 304 in relation with specific phenotypes using information available in the TwinsUK database ( Table  305 4). 306
The AGMAT-associated metabolites (4-guanidinobutanoate and beta-guanidinopropanoate) are 307 generated in the polyamine synthesis pathway (https://www.genome.jp/kegg-308 bin/show_pathway?hsa00330). This pathway also produces the compound putrescine, which has 309 been implicated in poor oral health and foul breath 28,29 . Consequently, we evaluated the 310 significance of the AGMAT-associated metabolites in oral health by testing them with PD status -311 the levels of both 4-guanidinobutanoate and beta-guanidinopropanoate were significantly higher in PD cases compared to controls (p=0.0003 and p=0.0006, respectively). Since eGFR (estimated 313 glomerular filtration rate) is calculated on the basis of serum creatinine, and these two commonly 314 used measures of renal function are negatively correlated, we wanted to investigate the 315 association between salivary creatinine and eGFR. We observed a similar strong negative 316 relationship between salivary creatinine and eGFR (p=1.6 x 10 -11 ), which was indicative of a 317 homeostasis between creatinine concentrations in serum and saliva. Furthermore, creatinine is 318 also known to be a marker of muscle mass and strength 30 . We, therefore, tested salivary 319 creatinine in relation with grip strength (a measure of muscle strength), which suggested a 320 positive correlation between them (p=0.01). 321
Apart from these findings, the remaining phenotypic associations that we tested were largely 322 negative, as follows: 323
The enzyme agmatinase (encoded by the AGMAT gene), which acts on the substrate agmatine, 324 has been implicated in the pathophysiology of mood disorders 31 . Moreover, studies have also 325 proposed agmatine as a novel neuromodulator 32 . We, therefore, tested the AGMAT-associated 326 metabolites in relation with a diagnosis of clinical depression or anxiety disorder, and responses 327 (on a ordinal scale) to questions in the Hospital Anxiety and Depression Scale (HADS) 328 questionnaire 33 . But, neither analysis showed any significant association (Table S5) . 329 ATP13A5, the locus that was associated with salivary creatinine, belongs to the family of 330
ATPases that regulate the activity of HMG-CoA reductase 34 , the main site of action of the 331 cholesterol-lowering class of drugs called statins. Statins are known to cause muscle dysfunction 332 (myopathy) in a small fraction of patients 35 . Given that ATP13A5 and statins both act in the same 333 biochemical pathway, we assessed whether salivary creatinine is also associated with statin usage, and could therefore be used as a biomarker for statin-induced myopathy. There was, 335 however, no association between salivary creatinine and statin usage (p=0.22). 336 5-Fluorouracil (5-FU) is a pyrimidine analogue that is a commonly used anticancer drug. It is 337 eliminated from the body via the pyrimidine degradation pathway, hence variants in genes 338 coding for the pyrimidine degradation enzymes (for instance, DPYS) are known to be associated 339 with the development of 5-FU toxicity 36 , which mainly manifests as gastrointestinal side effects. 340
Since we could not directly assess the DPYS-associated metabolites (3-ureidopropionate and 3-341 ureidoisobutyrate) in relation to the gastrointestinal side effects of 5-FU toxicity, we tested the 342 metabolites with a commonly observed phenotype of gastrointestinal dysfunction, irritable bowel 343 syndrome or IBS (ascertained using the ROME-III questionnaire 37 ). For both metabolites, we 344 observed that the levels were not significantly different in IBS "cases" compared to "controls" 345 (p>0.05, for both metabolites). However, this negative finding does not negate the possibility 346 that these metabolites could be of clinical use in predicting 5-FU toxicity. 347
Discussion
349
Here we report a genome-wide association analysis of 476 metabolites measured in saliva 350 samples of healthy population-based studies of European descent. We identified a total of 11 351 distinct genetic loci that regulate the level of 14 salivary metabolites, of which three loci were 352 associated with more than one metabolite each. 353
354
The fact that saliva is reflective of the concentration of biochemicals in blood forms the basis for 355 certain clinical applications of saliva that others have proposed previously such as therapeutic 356 monitoring of drugs 38 , cortisol measurement 39 and renal function monitoring 40 . Using salivary 357 metabolite data, we replicated the associations for certain well-established genetic loci that are 358 known to regulate the level of blood metabolites. Thus, our findings add further credence to the 359 notion that, as biofluids, a certain degree of homeostasis exists between blood and saliva. 360
361
Additionally, we identified some novel associations in our study, which have expanded our 362 knowledge of genetic influences on human metabolites. In particular, the association between the 363 DPYS locus and pyrimidine metabolites is intriguing because of its clinical relevance. Mutations evaluating 5-FU toxicity due to deficient DPYD activity 45 . In our study, variants in the DPYS ureidoisobutyrate). Therefore, studies to explore the utility of salivary measurements of these 372 metabolites as non-invasive tools for predicting 5-FU toxicity resulting from mutations that 373 affect DPYS activity are warranted. While we could not test 3-ureidopropionate and 3-374 ureidoisobutyrate in relation to the gastrointestinal side effects of 5-FU toxicity, we did not find 375 any association between these metabolites and a phenotype relevant to gut dysfunction (IBS 376 phenotype). Similarly, the observed association between salivary ribonate and the ENOSF1 377 locus, overexpression of which has been shown to cause resistance of tumour cell lines to 5-378 FU 27 , was further indicative of the possible role of saliva as a tool for drug monitoring. The other 379 novel finding of note was the association between the AGMAT locus and the metabolites 4-380 guanidinobutanoate and beta-guanidinopropanoate. The AGMAT-associated metabolites are 381 produced in the polyamine synthesis pathway, which also generates the compound putrescine 382 that has been implicated in oral health. Moreover, in our study, the AGMAT-associated 383 metabolites were correlated with PD status, a disease related to poor oral health. Together, these 384 findings suggest that the AGMAT-associated metabolites might serve as potential biomarkers for 385 oral health. On the other hand, though the agmatine pathway has been previously implicated in 386 mood disorders, we did not find any association between the AGMAT-associated metabolites and 387 either symptoms of or a prior diagnosis of clinical depression or anxiety disorder. Thus, evidence 388 based on the AGMAT-associated metabolites does not lend support to the hypothesis regarding a 389 potential link between pathways involved in maintaining oral health and regulation of mood 15, 18 . 390
There were a few other novel associations of interest in our study, such as the metabolite 391 gamma-carboxyglutamate (associated with the MGP locus, which is known to cause abnormal 392 vascular calcification in patients with cardiovascular disease 46 ), for which we could not assess the clinical significance since specific phenotypic information was not available in sufficient 394 numbers in those with salivary metabolite data. 395
396
Given that we identified some novel genetic associations for salivary metabolites i.e. genetic loci 397 that had not been reported in association with blood metabolites, it is indicative of the presence 398 of regulatory pathways that are specific to the salivary metabolome. For the novel genetic loci, in 399 most cases, the overlapping or the nearest gene transcript was expressed in one or more gut-400 related tissues, including salivary glands. However, for these loci, we did not find much evidence 401 for cis-eQTL effects specific to salivary or other gut tissues, whereby we could attribute their 402 association with the respective salivary metabolite(s) to transcriptional regulation of overlapping 403 / neighbouring genes. Interestingly, there is growing evidence to suggest that the human 404 metabolome is a reflection of an interaction between the host and the gut microbiome 7,47,48 -it 405 will, therefore, be worth exploring whether the salivary metabolites that were associated in our 406 study correlate with the composition of the salivary microbiome. Attempting to elucidate, in this 407 manner, biological processes that might mediate the observed associations between genetic loci 408 and salivary metabolites will help broaden our understanding of the underlying pathways. 409
410
In summary, our study has provided an initial map of genetic loci that regulate the salivary 411 metabolome. Based on what has been observed for other complex human traits, future studies 412 with larger sample sizes are expected to uncover additional genetic loci with much smaller 413 effects on salivary metabolites. Furthermore, our study also offered insights into hitherto 414 unknown biological pathways involved in maintaining the levels of salivary metabolites. While 415 we did explore, to an extent, the clinical relevance of a few salivary metabolites of interest, a 416 more comprehensive analysis with a wider range of phenotypic domains will help broaden our understanding of the relationship between the salivary metabolome and systemic health 418 conditions. 419 The 14 salivary metabolites that were identified in the discovery phase of our study mapped to 635 11 distinct genetic loci: of which, three loci (AGMAT, SLC2A9 and DPYS) were associated with 636 two metabolites each; and the remaining eight loci were each associated with one metabolite. 637
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The plots demonstrate the distribution of the significantly associated salivary metabolite with Table 1 : Summary of genetic loci that were significantly associated with salivary metabolite(s) in the discovery phase (TwinsUK) (Chr = Chromosome; EA = Effect Allele; EAF = Effect Allele Frequency; SE = Standard Error) For the primary stage of association analysis in the discovery phase (TwinsUK), locus-metabolite associations (mQTLs) were identified using a genome-wide and metabolome-wide significance threshold of p<10 -10 . *This mQTL was identified when the analysis was restricted to only the loci that were identified in the primary stage of association testing (significance threshold of p<10 -6 ) Table 2 : Summary of the discovery phase associations that were tested in the replication study (SHIP-2) (Chr = Chromosome; EA = Effect Allele; SE = Standard Error) ¶ Since information for the index variant (rs201298979) at the ABO locus was not available in the replication study, a proxy variant (rs9411378) that was in high LD (r 2 =0.95) with the index variant was used for the replication analysis. Replication in SHIP-2 could be attempted for 9 of the 14 mQTLs that were identified in the discovery phase (metabolites corresponding to the remaining five mQTLs were not measured in SHIP-2). For each of these nine mQTLs, the most significant variant-metabolite pair identified in the discovery phase was tested in SHIP-2 using salivary metabolite data that was not normalised for osmolality (since SHIP-2 saliva samples represented stimulated saliva). The TYMS gene encodes the enzyme thymidylate synthase, the main site of action of 5-fluorouracil. The ENOSF1 gene encodes the antisense RNA of TYMS Table 3 : Annotation of the genetic loci and the corresponding metabolites that were significantly associated in the discovery phase 1 obtained from the KEGG database 2 accessed from the NHGRI GWAS catalogue 3 accessed from the OMIM database The mQTLs that were identified in the discovery phase were annotated for the metabolite pathway, known disease associations for the locus from the GWAS and the OMIM databases, and the clinical significance of the locus, the metabolite or the biochemical pathway involved. Table 4 : Summary of the phenotypes that were tested in relation with specific salivary metabolites (Chr = Chromosome; eGFR = effective Glomerular Filtration Rate) The metabolites that were uniquely associated in saliva i.e. the ones for which a genetic association had not been previously reported in blood, were tested with phenotypes (diseases / traits / adverse drug effects) relating to the metabolite or its associated biochemical pathway, using information from the TwinsUK database. Figure 1 
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